H.C. Wainwright Downgrades FibroGen (FGEN) to Neutral

Go back to H.C. Wainwright Downgrades FibroGen (FGEN) to Neutral

FibroGen (FGEN) PT Lowered to $55 at Stifel

April 7, 2021 7:49 AM EDT

Stifel analyst Annabel Samimy lowered the price target on FibroGen (NASDAQ: FGEN) to $55.00 (from $70.00) while maintaining a Buy rating.

The analyst commented, "FGENs clarification of a different Roxadustat cardiovascular safety analysis is another unpleasant surprise, but it is not clear that it changes the... More

Mizuho Securities Downgrades FibroGen (FGEN) to Neutral

April 7, 2021 6:30 AM EDT

Mizuho Securities analyst Difei Yang downgraded FibroGen (NASDAQ: FGEN) from Buy to Neutral with a price target of $29.00.

The analyst comments "We are downgrading FGEN shares to Neutral, and reducing our PT from $72 to $29 as we see higher risk and uncertainty around timelines to... More